top of page

Direct to Bladder Therapies

About UroPharma

  • UroPharma has patented and developed the world’s first licensed ‘direct to bladder’ drug delivery system, that will be in the market by early 2023.

  • This overcomes clinical limitations and significant harms caused by the oral delivery of drugs intended for bladder therapy.

  • The design incorporates safety features intended to reduce costs associated with treating catheter acquired urinary tract infections caused by antibiotic resistance.

  • Urinary tract infections represent a substantial cost burden to the healthcare system and catheters are the biggest contributors to this global problem.

  • Urinary Tract Infections, Overactive Bladder, incontinence, Multiple Sclerosis and Spinal Cord Injury are a substantial reducer of quality of life with millions of people.


We’ll be very interested in your feedback and questions



Recent Posts

See All

The new UK anti-AMR strategy plan

Colleagues I’ve been wading through the UK #governments second 5-year anti-AMR action plan, “Confronting #AntimicrobialResistance 2024-2029, that was launched last week. It is rich in rhetoric and pac

Wise strategies in uro-oncology presented at EAU 24

The case for widening the #intravesical approach to #bladder diseases and disorders In the European Association of #Urology 2024 conference, intravesical chemotherapy “took centre stage:” https://www.

Comments


bottom of page